Charles Owen
CEO / Founder 272BIO
272BIO Limited
Reading, United Kingdom
24 profile visitsSpeakerAcademia / TTO / Emerging Companies / Public Research Organisation / Non-profit Oganisation
Founder of 272BIO with 30 years developing antibody drugs. Track record of taking drugs from initial concept to regulatory approval. 272BIO is a team of industry experts building a growing pipeline of clinically-validated VHH antibody-based medicines.
My organisation
272BIO is a UK-Belgium based antibody discovery and development company with full in-house CMC process development capability. The company is focused and has a track-record of developing differentiated products with a competitive advantage for indications and opportunities across animal health
About me
Additional questions
Interests
Pharmaceutical / TherapeuticsLivestockCompanion animalsAgro-Food Tech
Speaker sessions (1)
Wednesday, 20 May 2026
14:45 - 15:30
Masterclass 7: Beyond Monoclonal Antibodies: Next Generation Therapeutics for Animal Health - Multi-specificity for Complex Disease and Other Opportunities
Location:BMCC - 3rd Floor - Turtle RoomTrack:Masterclass
This talk explores the next generation of protein therapeutics designed for complex, multi-pathway diseases.
Sign-ups available from 1 Apr 2026, 00:00 to 20 May 2026, 15:30